DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Rhea-AI Summary
DBV Technologies (Euronext: DBV; Nasdaq: DBVT) will join the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review. The Scientific Council admitted DBV on March 12, 2026, and the index changes took effect on March 23, 2026.
The company said inclusion should boost visibility with French and European investors as it advances toward commercialization and continued development in food allergy therapies.
Positive
- Admitted to CAC Mid 60 effective March 23, 2026
- Admitted to SBF 120 effective March 23, 2026
- Potentially increased visibility among French and European investors
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
DBVT gained 5.76% while several biotech peers fell (e.g., OMER -3.05%, ANNX -4.57%, CAPR -2.47%), with only NGNE notably higher at 7.73%, suggesting a stock-specific reaction to the index inclusion news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Investor conferences | Positive | -3.1% | Participation in March investor conferences and related webcast access. |
| Mar 03 | Voting rights update | Neutral | +4.2% | Disclosure of total shares and voting rights as of Feb 28, 2026. |
| Feb 10 | Phase 3 data update | Positive | -5.0% | Additional positive VITESSE Phase 3 data for VIASKIN Peanut Patch. |
| Feb 09 | Investor summit | Positive | +7.1% | CEO fireside chat at Guggenheim Emerging Outlook: Biotech Summit. |
| Feb 05 | Voting rights update | Neutral | -0.9% | Disclosure of total shares and voting rights as of Jan 31, 2026. |
Recent news has produced mixed reactions: positive clinical and conference updates sometimes met with selling, while other neutral disclosures saw gains.
Over the past months, DBVT’s news flow included conference participations and governance disclosures alongside clinical milestones. A Feb 10 update on positive VITESSE Phase 3 data was followed by a -5.04% move, while a Guggenheim summit appearance on Feb 9 saw shares rise 7.11%. Routine voting-rights updates on Jan 31 and Feb 28 coincided with modest moves of -0.93% and 4.21%. Today’s index inclusion fits into this pattern of corporate and market-structure developments influencing trading.
Market Pulse Summary
This announcement highlights DBVT’s inclusion in the CAC Mid 60 and SBF 120 indices following the March 12, 2026 Euronext Paris review, effective March 23, 2026. Index membership can influence ownership through funds and structured products that track these benchmarks. Recent history shows mixed price responses to clinical and corporate updates, so observers may watch how index-related flows interact with upcoming clinical and commercialization milestones.
Key Terms
structured products financial
exchange traded funds financial
AI-generated analysis. Not financial advice.
Châtillon, France, March 24, 2026
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
- Changes went into effect on Monday, March 23, 2026
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026.
“We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets’ recognition of our continued progress,” stated Daniel Tassé, Chief Executive Officer of DBV Technologies. “We believe that inclusion in these widely followed indices will increase our visibility among the French and broader European investment communities as we prepare for commercialization and work to deliver meaningful innovation to the food allergy community.”
The CAC Mid 60 is a stock market index on Euronext Paris tracking the 60 most actively traded mid-cap French companies, ranked just below the top 60 French stocks (the CAC Large 60). The SBF 120 Index, which includes all companies in the CAC Large 60 and CAC Mid 60 Indices, is Free Float Market capitalization weighted, and serves as an underlying index for structured products, funds and exchange traded funds.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV’s admission to the CAC Mid 60 and SBF 120 Indices, anticipated to take effect post-market on Monday, March 23, 2026. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on October 28, 2025, and Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
VIASKIN is a registered trademark of DBV Technologies.
Investor Relations Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
When did DBV Technologies (DBVT) join the CAC Mid 60 and SBF 120 indices?
What does joining the CAC Mid 60 mean for DBVT shareholders?
How does inclusion in the SBF 120 affect DBV Technologies (DBVT)?
Which indices include DBV Technologies after the Euronext review in March 2026?
Will DBVT’s index inclusion change its trading timetable or listing venues?
